tvs-CTL Vaccine

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nametvs-CTL Vaccine
Drug Alias Nameanti-GD2 CAR T-cell therapy (University of Kansas)transduced vaccine-specific cytotoxic T-lymphocytes (University of Kansas)anti-GD2 CAR T-cell therapy (University of Kansas)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsDisialoganglioside GD2 modulatorsT lymphocytes stimulants
TargetsDisialoganglioside GD2
Therapy Area/IndicationsMelanomaNeuroblastomaOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Kansas
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Kansas
Inactive CompaniesN/A
Active IndicationsMelanomaNeuroblastomaOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A